These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 26508407)

  • 1. Clinical Relevance of Prognostic and Predictive Molecular Markers in Gliomas.
    Siegal T
    Adv Tech Stand Neurosurg; 2016; (43):91-108. PubMed ID: 26508407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical impact of molecular biomarkers in gliomas.
    Siegal T
    J Clin Neurosci; 2015 Mar; 22(3):437-44. PubMed ID: 25533211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice.
    Weller M; Stupp R; Hegi ME; van den Bent M; Tonn JC; Sanson M; Wick W; Reifenberger G
    Neuro Oncol; 2012 Sep; 14 Suppl 4(Suppl 4):iv100-8. PubMed ID: 23095825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT promoter methylation in gliomas: use with caution.
    Boots-Sprenger SH; Sijben A; Rijntjes J; Tops BB; Idema AJ; Rivera AL; Bleeker FE; Gijtenbeek AM; Diefes K; Heathcock L; Aldape KD; Jeuken JW; Wesseling P
    Mod Pathol; 2013 Jul; 26(7):922-9. PubMed ID: 23429602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation.
    Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M
    BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients.
    Takahashi Y; Nakamura H; Makino K; Hide T; Muta D; Kamada H; Kuratsu J
    World J Surg Oncol; 2013 Oct; 11():284. PubMed ID: 24160898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prognostic value of IDH mutations and MGMT promoter status in secondary high-grade gliomas.
    Juratli TA; Kirsch M; Geiger K; Klink B; Leipnitz E; Pinzer T; Soucek S; Schrock E; Schackert G; Krex D
    J Neurooncol; 2012 Dec; 110(3):325-33. PubMed ID: 23015095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MGMT promoter hypermethylation and its associations with genetic alterations in a series of 350 brain tumors.
    Mellai M; Monzeglio O; Piazzi A; Caldera V; Annovazzi L; Cassoni P; Valente G; Cordera S; Mocellini C; Schiffer D
    J Neurooncol; 2012 May; 107(3):617-31. PubMed ID: 22287028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation.
    Wick W; Meisner C; Hentschel B; Platten M; Schilling A; Wiestler B; Sabel MC; Koeppen S; Ketter R; Weiler M; Tabatabai G; von Deimling A; Gramatzki D; Westphal M; Schackert G; Loeffler M; Simon M; Reifenberger G; Weller M
    Neurology; 2013 Oct; 81(17):1515-22. PubMed ID: 24068788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial.
    Wiestler B; Capper D; Hovestadt V; Sill M; Jones DT; Hartmann C; Felsberg J; Platten M; Feiden W; Keyvani K; Pfister SM; Wiestler OD; Meyermann R; Reifenberger G; Pietsch T; von Deimling A; Weller M; Wick W
    Neuro Oncol; 2014 Dec; 16(12):1630-8. PubMed ID: 25028501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Neuropathology practice news 2-2014: ATRX, a new candidate biomarker in gliomas.
    Haberler C; Wöhrer A
    Clin Neuropathol; 2014; 33(2):108-11. PubMed ID: 24559763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma.
    Wiestler B; Capper D; Sill M; Jones DT; Hovestadt V; Sturm D; Koelsche C; Bertoni A; Schweizer L; Korshunov A; Weiß EK; Schliesser MG; Radbruch A; Herold-Mende C; Roth P; Unterberg A; Hartmann C; Pietsch T; Reifenberger G; Lichter P; Radlwimmer B; Platten M; Pfister SM; von Deimling A; Weller M; Wick W
    Acta Neuropathol; 2014 Oct; 128(4):561-71. PubMed ID: 25008768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence of biomarkers in high-grade gliomas and their impact on survival in a diverse SouthEast Asian cohort - a population-based study.
    Ang SYL; Lee L; See AAQ; Ang TY; Ang BT; King NKK
    BMC Cancer; 2020 Jan; 20(1):79. PubMed ID: 32005184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular prognostic factors of anaplastic oligodendroglial tumors and its relationship: a single institutional review of 77 patients from China.
    Li S; Yan C; Huang L; Qiu X; Wang Z; Jiang T
    Neuro Oncol; 2012 Jan; 14(1):109-16. PubMed ID: 22039037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Updates in prognostic markers for gliomas.
    Aquilanti E; Miller J; Santagata S; Cahill DP; Brastianos PK
    Neuro Oncol; 2018 Nov; 20(suppl_7):vii17-vii26. PubMed ID: 30412261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic, prognostic and predictive relevance of molecular markers in gliomas.
    Brandner S; von Deimling A
    Neuropathol Appl Neurobiol; 2015 Oct; 41(6):694-720. PubMed ID: 25944653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Promoter hypermethylation of the EMP3 gene in a series of 229 human gliomas.
    Mellai M; Piazzi A; Caldera V; Annovazzi L; Monzeglio O; Senetta R; Cassoni P; Schiffer D
    Biomed Res Int; 2013; 2013():756302. PubMed ID: 24083241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary glioblastoma with oligodendroglial differentiation has better clinical outcome but no difference in common biological markers compared with other types of glioblastoma.
    Laxton RC; Popov S; Doey L; Jury A; Bhangoo R; Gullan R; Chandler C; Brazil L; Sadler G; Beaney R; Sibtain N; King A; Bodi I; Jones C; Ashkan K; Al-Sarraj S
    Neuro Oncol; 2013 Dec; 15(12):1635-43. PubMed ID: 24158110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.
    Kim HS; Kwon MJ; Song JH; Kim ES; Kim HY; Min KW
    Pathol Res Pract; 2018 Jun; 214(6):881-888. PubMed ID: 29650441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas.
    Appay R; Dehais C; Maurage CA; Alentorn A; Carpentier C; Colin C; Ducray F; Escande F; Idbaih A; Kamoun A; Marie Y; Mokhtari K; Tabouret E; Trabelsi N; Uro-Coste E; Delattre JY; Figarella-Branger D;
    Neuro Oncol; 2019 Dec; 21(12):1519-1528. PubMed ID: 31832685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.